109 results about "Archaea" patented technology

The present disclosure provides CasX proteins, nucleic acids encoding the CasX proteins, and modified host cells comprising the CasX proteins and / or nucleic acids encoding same. CasX proteins are useful in a variety of applications, which are provided. The present disclosure provides CasX guide RNAs that bind to and provide sequence specificity to the CasX proteins, nucleic acids encoding the CasX guide RNAs, and modified host cells comprising the CasX guide RNAs and / or nucleic acids encoding same. CasX guide RNAs are useful in a variety of applications, which are provided. The present disclosure provides archaeal Cas9 polypeptides and nucleic acids encoding same, as well as their associated archaeal Cas9 guide RNAs and nucleic acids encoding same.

Provided are recombinant cells that are anaerobic archaea, wherein: the recombinant cells have a gene that encodes isoprene synthase, a gene that encodes monoterpene synthase, a gene that encodes sesquiterpene synthase, a gene that encodes diterpene synthase, a gene that encodes squalene synthase, or a gene that encodes phytoene synthase as a first foreign gene; and the recombinant cells are capable of expressing the first foreign gene and producing isoprene or terpenes having 10, 15, 20, 30, or 40 carbon atoms.

The present invention relates to a method for diagnosing Parkinson's disease through bacterial metagenome analysis and, more specifically, to a method for performing bacterial metagenome analysis by using a sample derived from a subject so as to analyze increases and decreases in the amount of extracellular vesicles derived from specific bacteria, thereby diagnosing Parkinson's disease. The extracellular vesicles secreted from microbes, such as bacteria and archaea, present in the environment are absorbed into the body so as to be distributed to the brain, thereby directly influencing inflammatory responses and brain functions, and since early diagnosis of Parkinson's disease, which is characterized by inflammation, before symptoms occur is difficult, effective treatment has been difficult. Through the bacteria-derived extracellular vesicle metagenome analysis using a human-derived sample, according to the present invention, the risk of onset of Parkinson's disease can be predicted inadvance such that Parkinson's disease risk groups are diagnosed and predicted in an early stage, thereby enabling the time of onset of the disease to be delayed or the onset of the disease to be prevented through appropriate management, and early diagnosis is enabled even after the onset of the disease, thereby enabling the incidence of Parkinson's disease to be lowered and therapeutic effects tobe increased.